Imbruvica (Ibrutinib) 140 mg Capsules are used in the treatment of various blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and chronic graft-versus-host disease (GVHD). Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that works by blocking the BTK protein, which is involved in the survival and spread of cancer cells. By targeting this protein, Imbruvica helps in reducing the growth of malignant cells, improving outcomes for patients with these conditions.

• Effective for CLL: Imbruvica is a preferred treatment option for chronic lymphocytic leukemia (CLL), helping to reduce the number of abnormal white blood cells.

• Treats MCL: Highly effective in treating mantle cell lymphoma (MCL), a rare but aggressive form of lymphoma.

• Targeted therapy: As a BTK inhibitor, it specifically targets cancer cells, reducing the effect on healthy cells and minimizing side effects.

• Improved survival rates: It has demonstrated significant improvement in survival and progression-free survival in patients with certain blood cancers.

• Dosage: The typical starting dose for Imbruvica 140 mg Capsules is one 140 mg capsule once daily.

• Administration: Take the capsule orally with a full glass of water. It can be taken with or without food.

• Consistency: It’s important to take Imbruvica at the same time every day to maintain steady drug levels in the bloodstream.

• Do not crush or chew the capsules. Swallow them whole.

• Strength: 140 mg per capsule

• Form: Oral capsule

• Common Dosage: Typically, one 140 mg capsule daily, but this may vary based on individual medical conditions and doctor recommendations.

• Adjustments: Dosage may be adjusted based on your response to treatment or if side effects occur.

• Duration: The treatment length can vary, but many patients will require long-term therapy as part of a chronic disease management plan.

• Pregnancy Category D: Imbruvica should not be used during pregnancy, as it may harm an unborn baby.

• Risk of bleeding: Imbruvica can increase the risk of serious bleeding, especially when used in combination with other medications that affect blood clotting.

• Infection risks: Ibrutinib may increase the risk of infections. Inform your healthcare provider if you have a history of infections or are at risk of infections.

• Monitor for heart problems: Some patients may experience heart problems, including atrial fibrillation (irregular heartbeat), which should be monitored regularly.

• Drug interactions: Inform your doctor of all medications, including anticoagulants, antiplatelets, or other cancer treatments, as there may be significant drug interactions.

• Common side effects: Diarrhea, fatigue, muscle or joint pain, headache, and nausea.

• Serious side effects: Bleeding (bruising, nosebleeds, blood in urine), heart problems (fast or irregular heartbeat), infections, liver problems, and low blood counts.

• Less common: Rash, mouth sores, swollen lymph nodes, and digestive problems.

• Urgent medical attention: Seek medical help immediately if you experience severe bleeding, chest pain, shortness of breath, or signs of infection like fever or chills.

• Store Imbruvica 140 mg Capsules at room temperature (20°C to 25°C), away from heat, moisture, and direct light.

• Keep the capsules in their original bottle, tightly closed.

• Ensure the medication is out of reach of children.

• Do not use after the expiration date printed on the packaging.

Q1. How does Imbruvica work to treat cancer?
A: Imbruvica works by inhibiting Bruton’s tyrosine kinase (BTK), a protein involved in the survival and proliferation of cancer cells. By blocking this protein, it reduces the spread of cancer cells, particularly in cancers like CLL and MCL.

Q2. Is Imbruvica suitable for all blood cancers?
A: Imbruvica is most effective in treating cancers like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and chronic graft-versus-host disease (GVHD). It may not be effective for all blood cancers, so treatment plans should be discussed with a doctor.

Q3. What should I do if I miss a dose of Imbruvica?
A: If you miss a dose, take it as soon as you remember, unless it’s almost time for your next dose. Do not take two doses at once to make up for a missed dose.

Q4. Can I stop taking Imbruvica once I feel better?
A: No, you should not stop taking Imbruvica without consulting your doctor, even if you feel better. Stopping the medication may allow cancer cells to resume growth.

Q5. What are the long-term effects of taking Imbruvica?
A: Long-term use of Imbruvica can lead to improved survival rates in certain cancers but may also require monitoring for side effects such as heart problems and bleeding risks.